Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incannex Healthcare Inc. - Common Stock (NQ:IXHL)

0.3524 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incannex Healthcare Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More ↗
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
News headline image
Incannex Stock Trading Higher On Entering A Lease For First Psychedelic-Assisted Psychotherapy Clinic ↗
Incannex Healthcare Ltd (NASDAQ: IXHL) (ASX:IHL) announced that its subsidiary company, Clarion Clinics Group Pty Ltd, has entered a lease for riverfront premises in Abbottsford, Melbourne. 
Via Benzinga
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics... 
Via TheNewswire.com
News headline image
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A 
Via News Direct
News headline image
Why Incannex Healthcare Shares Are Gaining Today ↗
 
Via Benzinga
News headline image
Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products ↗
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. 
Via Talk Markets
News headline image
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More ↗
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
News headline image
April Psychedelic Drug Stocks Recap: The Ups And Downs ↗
Via Talk Markets
News headline image
New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market ↗
Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual... 
Via Benzinga
News headline image
Largest Psychedelic Stocks -3.4% In March ↗
The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts. 
Via Talk Markets
News headline image
Cannabis Category Performances Ranged From +8.6% To -7.0% This Week ↗
The 5 categories in the cannabis sector perform quite differently from each other and this week was a prime example. 
Via Talk Markets
News headline image
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More ↗
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
News headline image
Incannex Healthcare Prepares To Launch Psychedelics Clinics Via New Subsidiary ↗
Australia-based biopharma giant Incannex Healthcare Ltd. (NASDAQ: IXHL) has plans to commercialize its psychedelic-assisted psychotherapy business through a new subsidiary venture under the leadership... 
Via Benzinga
News headline image
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder ↗
Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies. 
Via Benzinga
News headline image
All 5 Cannabis Categories Down Last Week; Only 1 Is UP YTD ↗
The 5 categories in the cannabis sector perform quite differently from each other. Only 1 is up YTD. 
Via Talk Markets
News headline image
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More ↗
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
News headline image
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets ↗
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
News headline image
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use 
Via News Direct
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use
Incannex Healthcare Ltd (ASX:IHL NASDAQ:IXHL) CEO and MD Joel Latham sits down with Proactive to talk about the development and manufacturing deal it has struck with pharma giant Catalent to produce... 
Via TheNewswire.com
News headline image
Incannex Engages Catalent For Development And Manufacture Of Psilocybin Drug For Clinical Trials ↗
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has... 
Via Benzinga
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial, testing the safety and efficacy of its IHL-657A drug candidate in patients... 
Via TheNewswire.com
News headline image
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial
Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial 
Via News Direct
News headline image
Incannex Starts Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis ↗
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has commenced a phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket ↗
Gainers Inpixon (NASDAQ: INPX) shares rose 41% to $2.20 in pre-market trading after gaining 6% on Tuesday. Inpixon, last month, secured a purchase order valued at over $1m for its RTLS products from a... 
Via Benzinga
News headline image
Australian Psychedelics: Phase 2 Trial On Psilocybin For Anxiety Will Soon Share Results ↗
Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare (NASDAQ: 
Via Benzinga
News headline image
Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More ↗
Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.